OVID THERAPEUTICS INC (OVID)
Health Care · NASDAQ
A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental epileptic encephalopathies, and psychosis.
What OVID THERAPEUTICS INC does
Ovid Therapeutics is a biopharmaceutical company dedicated to discovering and developing differentiated small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company focuses on targeting neuronal hyperexcitability through novel mechanisms of action, including a differentiated portfolio of KCC2 (potassium-chloride cotransporter 2) activators. With two programs currently in clinical trials, the company is pursuing therapeutic candidates for drug-resistant focal onset seizures, developmental and epileptic encephalopathies (including tuberous sclerosis complex seizures and infantile spasms), psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia.
Themes: ["Epilepsy treatment / seizure disorders","Rare neurological conditions","CNS / neuropsychiatric disorders","Psychosis treatment","Neuronal hyperexcitability","Ion channel / transporter biology"]
Fundamentals
- Price$2.60 as of 2026-07-09 close
- Market cap$500M as of 2026-07-10
- 1-year return+494.4% as of 2026-07-09 close
- Net margin-240.1% as of 2026-07-10
- ROE-22.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+1199.6% as of 2026-07-10
- Revenue CAGR (3y)+69.0% SEC XBRL
- Beta0.25 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with accumulated deficit of $338.7 million and net losses of $17.0 million in Q1 2026; dependent on additional funding through equity offerings, debt financings, collaborations, or strategic alliances to continue operations.","Clinical development risk: significant R&D expenses required for ongoing and planned preclinical and clinical trials; success of late-stage programs and pipeline advancement is uncertain.","Competitive CNS drug development landscape with relatively few new therapeutic classes approved in neurology and neuropsychiatry; execution risk on commercialization and market adoption of novel mechanisms."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.